Los Angeles Capital Management LLC Grows Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Los Angeles Capital Management LLC raised its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 54.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 103,005 shares of the company's stock after buying an additional 36,240 shares during the period. Los Angeles Capital Management LLC owned about 0.20% of Stoke Therapeutics worth $1,266,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of STOK. Lynx1 Capital Management LP raised its holdings in shares of Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock valued at $70,052,000 after acquiring an additional 1,488,371 shares in the last quarter. Redmile Group LLC raised its holdings in Stoke Therapeutics by 93.2% in the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company's stock worth $68,486,000 after purchasing an additional 2,447,543 shares in the last quarter. Baker BROS. Advisors LP lifted its position in shares of Stoke Therapeutics by 65.9% in the 1st quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company's stock worth $45,474,000 after purchasing an additional 1,338,309 shares during the period. Vanguard Group Inc. boosted its stake in shares of Stoke Therapeutics by 4.1% during the 1st quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company's stock valued at $23,160,000 after purchasing an additional 67,052 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Stoke Therapeutics during the second quarter valued at about $19,835,000.

Insider Buying and Selling

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares of the company's stock, valued at approximately $125,131,843.05. This trade represents a 17.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 11.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on STOK shares. Leerink Partnrs upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an "outperform" rating and a $18.00 target price for the company. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $20.83.

Stoke Therapeutics Stock Performance

Shares of STOK traded down $1.60 during trading hours on Friday, hitting $12.32. The company had a trading volume of 484,218 shares, compared to its average volume of 753,299. The stock has a market capitalization of $652.59 million, a price-to-earnings ratio of -6.41 and a beta of 0.95. The firm has a fifty day moving average price of $13.11 and a 200-day moving average price of $13.78. Stoke Therapeutics, Inc. has a 52-week low of $3.77 and a 52-week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million during the quarter, compared to analysts' expectations of $3.46 million. Research analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.